Form 10-Q ARS Pharmaceuticals, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
William Blair Reiterates Outperform Rating on ARS Pharmaceuticals Inc (SPRY)
November 10, 2025 7:29 AM ESTWilliam Blair analyst Tim Lugo reiterated an Outperform rating on ARS Pharmaceuticals Inc (NASDAQ: SPRY).
The analyst comments "We attended the American College of Allergy, Asthma, and Immunology (ACAAI) 2025 annual meeting where ARS presented the initial results from the neffyExperience program alongside a number of posters on neffy. Based on a... More
